Replimune Group, a biotech firm based in Woburn, is set to lay off a total of 224 employees—more than triple its initial plan of 63—following a regulatory setback. The FDA recently rejected the company’s application for licensing RP1, a drug designed to treat advanced melanoma, citing insufficient evidence of its effectiveness. The layoffs, affecting both its headquarters and a manufacturing facility, come as the company grapples with the aftermath of this second rejection and a challenging regulatory process. CEO Sushil Patel expressed regret over the impact on employees, indicating a significant scale-back in U.S. manufacturing operations.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://patch.com/massachusetts/woburn/after-turndown-its-new-drug-biotech-company-triples-job-cuts
